1. Home
  2. CCEL vs ATRA Comparison

CCEL vs ATRA Comparison

Compare CCEL & ATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CCEL
  • ATRA
  • Stock Information
  • Founded
  • CCEL 1989
  • ATRA 2012
  • Country
  • CCEL United States
  • ATRA United States
  • Employees
  • CCEL N/A
  • ATRA N/A
  • Industry
  • CCEL Managed Health Care
  • ATRA Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • CCEL Health Care
  • ATRA Health Care
  • Exchange
  • CCEL Nasdaq
  • ATRA Nasdaq
  • Market Cap
  • CCEL 39.9M
  • ATRA 40.1M
  • IPO Year
  • CCEL 1997
  • ATRA 2014
  • Fundamental
  • Price
  • CCEL $4.89
  • ATRA $9.22
  • Analyst Decision
  • CCEL Strong Buy
  • ATRA Buy
  • Analyst Count
  • CCEL 1
  • ATRA 5
  • Target Price
  • CCEL $8.50
  • ATRA $17.75
  • AVG Volume (30 Days)
  • CCEL 13.3K
  • ATRA 36.6K
  • Earning Date
  • CCEL 07-14-2025
  • ATRA 08-11-2025
  • Dividend Yield
  • CCEL 19.76%
  • ATRA N/A
  • EPS Growth
  • CCEL N/A
  • ATRA N/A
  • EPS
  • CCEL 0.01
  • ATRA N/A
  • Revenue
  • CCEL $32,102,750.00
  • ATRA $199,732,000.00
  • Revenue This Year
  • CCEL $2.49
  • ATRA N/A
  • Revenue Next Year
  • CCEL $0.95
  • ATRA N/A
  • P/E Ratio
  • CCEL $560.42
  • ATRA N/A
  • Revenue Growth
  • CCEL 2.33
  • ATRA 475.53
  • 52 Week Low
  • CCEL $4.75
  • ATRA $5.01
  • 52 Week High
  • CCEL $9.43
  • ATRA $18.71
  • Technical
  • Relative Strength Index (RSI)
  • CCEL 45.67
  • ATRA 68.21
  • Support Level
  • CCEL $4.87
  • ATRA $7.54
  • Resistance Level
  • CCEL $6.35
  • ATRA $8.25
  • Average True Range (ATR)
  • CCEL 0.27
  • ATRA 0.46
  • MACD
  • CCEL -0.02
  • ATRA 0.09
  • Stochastic Oscillator
  • CCEL 8.11
  • ATRA 96.01

About CCEL Cryo-Cell International Inc.

Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The Public cord blood banking segment consists of cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.

About ATRA Atara Biotherapeutics Inc.

Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).

Share on Social Networks: